Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.
Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC
April 29th 2023Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/
Read More
O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses
April 21st 2023Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.
Read More
Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers
April 20th 2023To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.
Read More
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
April 19th 2023Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Read More
Robert L. Coleman, MD, FACOG, FACS, discusses a subgroup analysis of the SORAYA trial, which was presented during the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, and where the field is headed in attempt to address unmet needs for this patient population.
Read More
Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer
March 10th 2023Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.
Read More
Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.
Read More
ADCs Advance HR+/HER2– Breast Cancer Treatment Paradigm
March 7th 2023As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.
Read More
Wang Details Caveats to Standards of Care for Treating Patients With MCL
February 28th 2023When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.
Read More
Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOC
February 27th 2023Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.
Read More
New Technology Advances Prostate Cancer Care But Questions Linger
February 21st 2023Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.
Read More
Elacestrant Secures a Place for ER+, HER2–, ESR1-Mutated Advanced/Metastatic Breast Cancer
February 15th 2023François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Read More
Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma
February 9th 2023Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.
Read More
Investigators Unpack Potential Role of Nab-Sirolimus for Solid Tumors With TSC1/2 Mutations
January 27th 2023Brian Schulte, MD, discusses the relevance of these mutations and an actively enrolling phase 2 PRECISION-1 basket trial investigating the efficacy of nab-sirolimus in solid tumors.
Read More